Chinese-English  (Yokel Shenzhen Translation )

 “SDTL 生命因子 ” 是由我国著名植物小分子科学家、石家庄国家高新技术产业开发区牛满江实验室生物小分子研究室主任释慧远教授独创研究的生命细胞调节素。由广州医药工业研究所药理研究室研究实验证实，抗低压缺氧效果显著，在缺氧环境中能使实验动物缺氧生存率提高 75% ，在低压缺氧环境中的生存时间延长率提高 96% ，此实验对预防高原缺氧及高原缺氧综合征的治疗具有重大的临床意义。 ( “ SDTL 生命因子 --- 克服高原缺氧难题“ 翻译片段 )

(翻译片段)

English-Chinese (Yokel Shenzhen Translation )

 Biomakers trump behavior in mental ilness diagnosis

Delusions, hallucinations, disorgnized thinking and other psychotic symptoms can result from schizophrenia, Alzheimer disease, bipolar disorder, manic, depression or dementia.

The anwsers to doctors’ questions can help whittle down the categories somewhat, but it’s far from a perfect science. Less than a third of individuals with these disorders respond to medications most likely because they are being treated for the wrong one The treatment for each disease can be drastically different,  so pinning down the dianosis is crucial......

生物标志物-----精神疾病的诊断利器

精神分裂症，alzheimer病， 双向情感障碍，燥郁症，燥型痴呆症等病症易导至幻想，幻觉，思维紊乱，及其它精神错乱病症。糖尿病及梅毒甚至也可能从为各类精神疾病的诱因

虽然医生们可以根椐患者针对所提问题的答案，从一定程度上缩小其病症范围，但那远非一种完美的科学方法。经验告诉我们，精神紊乱患者中,只有不到三分之一的人会对药物作出反应,究其原因，极可能是没有对症下药。针对每一种疾病，都可能存在相差极大的不同治疗方法， 因而精确的诊断至关重要......(翻译片段)

Chinese-English  (Yokel Shenzhen Translation )

在金湾区如火如荼的发展中，可供发展的土地日益减少！而能背靠青山，面朝大海，占据黄金海岸线的更绝无仅有！

紫竹湾背倚青葱翠绿的山脉，面向浩瀚的南中国海，十几公里长的海岸线蜿蜒而上，将青山、大海、人文巧妙串连，独具稀缺优美环境，无敌海景、俊美山景一览无余，专享完美自然生态....

(翻译片段)

lying against the green mountain range and facing the boundless South China Sea, Zhizu Bay is  backgrounded by a  coastline that winds up over ten kilometers in distance----lining up the mountains, the sea, and the human culture  landscapes in a smart  way,  to form a perfect natural ecological environment with  unmatched gorgeous view of the sea and the mountains---which  can all  be seen at a glance.....

English-Chinese (Yokel Shenzhen Translation )

 Immetech International Inc.(AmEx: IMM) is a pharmaceutical company focused on commercializing a new class of oral drugs to treat diseases and varieties of other diseases. Global annual sales in 2004 for anti-infective drugs are estimated to be US $46 billion. The Company is committed to developing oral drugs to treat diseases for which there is no cure or to replace existing drugs that have become less effective.